Trelagliptin succinate

Modify Date: 2024-01-02 09:36:34

Trelagliptin succinate structure	Common Name	Trelagliptin succinate
	CAS Number	1029877-94-8	Molecular Weight	475.470
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₂H₂₆FN₅O₆	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Trelagliptin succinate

Trelagliptin(SYR-472) is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D). IC50 value:Target: DPP4Two Phase II clinical studies have been completed with Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus. Phase III clinical studies with trelagliptin in Japan to evaluate its safety and efficacy in a once-weekly oral treatment regimen. Currently, all available DPP-4 inhibitors are dosed once-daily. A once-weekly treatment, such as trelagliptin, would provide patients with a convenient treatment alternative and has the potential to improve treatment compliance.

Name	2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile,butanedioic acid
Synonym	More Synonyms

Description	Trelagliptin(SYR-472) is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D). IC50 value:Target: DPP4Two Phase II clinical studies have been completed with Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus. Phase III clinical studies with trelagliptin in Japan to evaluate its safety and efficacy in a once-weekly oral treatment regimen. Currently, all available DPP-4 inhibitors are dosed once-daily. A once-weekly treatment, such as trelagliptin, would provide patients with a convenient treatment alternative and has the potential to improve treatment compliance.
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Dipeptidyl Peptidase Research Areas >> Metabolic Disease
References	[1]. Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus [2]. Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus [3]. Long-term Study of SYR-472 [4]. SYR-472 Open-label Study

Description

Related Catalog

Signaling Pathways >> Metabolic Enzyme/Protease >> Dipeptidyl Peptidase

Research Areas >> Metabolic Disease

References

[1]. Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus

[2]. Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

[3]. Long-term Study of SYR-472

[4]. SYR-472 Open-label Study